Moderna, Inc.
The FDA approved Moderna’s mRNA flu vaccine mFLUSIVA for adults 50 to 64 and granted accelerated approval for ages 65+. In a phase 3 trial of over 40,000 adults, it was 26% more effective than a licensed standard-dose flu vaccine. Moderna said it generated stronger antibodies than Sanofi’s high-dose vaccine in older adults.
Pfizer Korea’s RSV vaccine Abrysvo received MFDS marketing authorization on Aug. 13 for adults 60+ and high-risk adults 18-59. The article says this adds to competition with GSK’s Arexvy and Moderna’s mRESVIA. For infants, it contrasts maternal Abrysvo (MATISSE: 81.8% risk reduction to day 90) with Sanofi’s Beyfortus and MSD’s Enflonsia, and notes policy talks on NIP and reimbursement.
Lyme disease cases in Canada rose from 144 in 2009 to 5,809 in 2024, with 7,105 preliminary cases for 2025, according to PHAC data. The article says no human Lyme vaccine is currently approved. Pfizer and Valneva’s PF-07307405 completed Phase 3 with over 70% efficacy after four doses, and Moderna has Phase 2 candidates mRNA-1975 and mRNA-1982.
Over the past 7 days, alphai's AI scored 8 news stories mentioning MRNA (Moderna, Inc.). Coverage has skewed bullish: 5 bullish, 3 neutral, and 0 bearish.
Recent MRNA coverage spans regulation and technology.
In the last 30 days, MRNA insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($28.7M). The most active reporter was Bancel Stephane, Chief Executive Officer, with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Regulatory approval expands Moderna’s mRNA franchise beyond COVID-19 and creates a near-term commercialization and uptake catalyst for older adults.
The competitive set for adult RSV vaccines is clarified, but the article provides no new Moderna regulatory or trial update.
Pipeline progress in Phase 2 supports longer-dated optionality, but without new Phase 2 data or timelines it is incremental.
Regulatory clearance to begin Phase I supports pipeline optionality, but the article frames valuation risk as investors questioning whether the stock is already pricing in future execution.
Phase 2 status for two separate Lyme candidates supports continued R&D optionality, but it is less immediate than Phase 3.
alphai scores every news story that mentions MRNA with an AI model for sentiment and relevance, and aggregates insider trades from Moderna, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The FDA approved Moderna’s mRNA flu vaccine mFLUSIVA for adults 50 to 64 and granted accelerated approval for ages 65+. In a phase 3 trial of over 40,000 adults, it was 26% more effective than a licensed standard-dose flu vaccine. Moderna said it generated stronger antibodies than Sanofi’s high-dose vaccine in older adults.
6 min readPfizer Korea’s RSV vaccine Abrysvo received MFDS marketing authorization on Aug. 13 for adults 60+ and high-risk adults 18-59. The article says this adds to competition with GSK’s Arexvy and Moderna’s mRESVIA. For infants, it contrasts maternal Abrysvo (MATISSE: 81.8% risk reduction to day 90) with Sanofi’s Beyfortus and MSD’s Enflonsia, and notes policy talks on NIP and reimbursement.
6 min readLyme disease cases in Canada rose from 144 in 2009 to 5,809 in 2024, with 7,105 preliminary cases for 2025, according to PHAC data. The article says no human Lyme vaccine is currently approved. Pfizer and Valneva’s PF-07307405 completed Phase 3 with over 70% efficacy after four doses, and Moderna has Phase 2 candidates mRNA-1975 and mRNA-1982.
7 min readHealth Canada cleared Moderna (MRNA) to start a Phase I trial of its mRNA Ebola vaccine targeting the Bundibugyo virus, according to the company. The article cites Moderna’s volatile stock performance and a Simply Wall St fair value estimate of $44.25 versus a $63.32 share price, noting valuation concerns and risks around vaccine uptake and pricing.
4 min readThe article says reported Lyme disease cases in Canada rose from 144 in 2009 to 5,809 in 2024, with 2025 preliminary cases at 7,105, citing PHAC data. It notes no human Lyme vaccine is currently approved. It describes Pfizer and Valneva’s co-developed vaccine PF-07307405 completing Phase 3 as of March 2026, and Moderna’s mRNA-1975 and mRNA-1982 in Phase 2.
6 min readOn Aug. 5, the FDA approved Moderna’s mRNA influenza vaccine, mFlusiva, for adults 50 and up, with U.S. pharmacy availability expected for the 2026-2027 flu season. In a trial of 40,000+ adults ages 50-64, it reduced flu risk by 27% versus standard shots but caused more side effects. FDA approval for 65+ is accelerated pending further comparisons.
6 min readThe FDA approved Moderna’s mRNA flu vaccine mFLUSIVA for adults over 50, citing documented superiority versus standard-dose flu vaccines. Moderna said it is about 27% more effective. The article says mRNA production avoids egg-based manufacturing, enabling faster updates to emerging strains. It also notes prior FDA review delays and vaccine skepticism.
6 min readThe article reviews health headlines. It says Trump signed an executive order to further review and potentially split the MMR vaccine into separate shots, but states still set school vaccine requirements. It notes CDC-reported Candida auris cases exceed 3,000 this year. It reports FDA approval of Moderna’s mRNA flu vaccine mFlusiva for adults 50-64, about 27% more effective. It also covers FDA approval of Tudriqev, a genetically modified herpes virus for advanced melanoma.
5 min readABC News reports that the FDA has approved Moderna’s first mRNA flu vaccine, according to Dr. Tara Narula. The approval makes Moderna’s product the first-ever mRNA flu shot from the company, which could affect investor expectations for its vaccine pipeline and future sales.
2 min readThe FDA approved Moderna’s mRNA influenza vaccine mFlusiva for adults 50 and older. Adults 50 to 64 received standard approval based on efficacy, with 26.6% reported efficacy versus a licensed standard-dose flu vaccine. Adults 65+ received accelerated approval based on antibody response, contingent on a confirmatory postmarketing trial over two flu seasons. Availability depends on supply and ACIP recommendations.
6 min read
